Yilmaz 2002.

Study characteristics
Methods	RCT, placebo‐controlled, open‐label trial Date of study: unreported Location: Turkey
Participants	Randomised: 50 participants (no description of the study population) Inclusion/exclusion criteria Not stated Dropouts and withdrawals Not stated
Interventions	Intervention A. Acitretin (n = 50), orally, 0.5‐0.7 mg/kg, daily Control intervention B. Placebo (n = 50). Co‐intervention PUVA, twice weekly, 8‐MOP at a dosage of 0.4 ‐ 0.6 g/kg, 2 hours before UVA exposure
Outcomes	Time of assessments not stated Primary or secondary outcomes of the trial Not clearly defined Outcomes of the trial Complete remission
Notes	Funding source: not stated Declarations of interest: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote (abstract): "The patients were equally allocated to treatment groups in the study" Comment: no description of the method used to guarantee random sequence generation
Allocation concealment (selection bias)	Unclear risk	Quote (abstract): "The patients were equally allocated to treatment groups in the study" Comment: no description of the method used to guarantee allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote (abstract): "We performed an open, controlled study..." Comment: not blinded, subjective outcome
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote (abstract): "We performed an open, controlled study..." Comment: not blinded, subjective outcome
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Randomly assigned 50 Comment: no description of the number of participants analysed, no description of the method used to manage missing data
Selective reporting (reporting bias)	Unclear risk	Comment: only an abstract available